Mitomycin (Mutamycin, Mitomycin-C)
Other Medications · Approved since 1974
Description
Mitomycin is an antitumor antibiotic chemotherapy agent derived from Streptomyces caespitosus that functions as an alkylating agent. In colorectal cancer treatment, it is primarily used in specialized applications including pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis and hepatic arterial infusion for liver metastases. Mitomycin may also be used in combination regimens for advanced or metastatic colorectal cancer, particularly in salvage therapy situations.
Mechanism of Action
Mitomycin acts as a bioreductive alkylating agent that becomes activated in hypoxic conditions typical of tumor environments. Once activated by cellular reductases, it forms DNA cross-links between complementary DNA strands, preventing DNA replication and transcription, ultimately leading to cell death.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Mutamycin, Mitomycin-C |
| Category | Other Medications |
 Status | FDA Approved |
 EMA Status | EMA Approved |
 Spain Access | Hospital use other indication |
| Administration | IV |
| Year Approved | 1974 |
| Clinical Trials | 11 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.